BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10652633)

  • 21. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit.
    Sawyer EJ; Poulsom R; Hunt FT; Jeffery R; Elia G; Ellis IO; Ellis P; Tomlinson IP; Hanby AM
    J Pathol; 2003 May; 200(1):59-64. PubMed ID: 12692842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystosarcoma phyllodes of the breast: a rare diagnosis: case studies and review of literature.
    Kraemer B; Hoffmann J; Roehm C; Gall C; Wallwiener D; Krainick-Strobel U
    Arch Gynecol Obstet; 2007 Dec; 276(6):649-53. PubMed ID: 17549503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast.
    Feakins RM; Wells CA; Young KA; Sheaff MT
    Hum Pathol; 2000 Oct; 31(10):1214-22. PubMed ID: 11070114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low expression of bcl-2 in Brca1-associated breast cancers.
    Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X
    Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
    Kleer CG; Giordano TJ; Braun T; Oberman HA
    Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes.
    Arun B; Kilic G; Yen C; Foster B; Yardley D; Gaynor R; Ashfaq R
    Cancer; 2003 Dec; 98(12):2554-9. PubMed ID: 14669273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.
    Liu S; Edgerton SM; Moore DH; Thor AD
    Clin Cancer Res; 2001 Jun; 7(6):1716-23. PubMed ID: 11410511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological indicators of aggressiveness in T1 ductal invasive breast cancer.
    Bucci B; Carico E; Rinaldi A; Froio F; Puce YM; D'Agnano I; Vecchione A; Brunetti E
    Anticancer Res; 2001; 21(4B):2949-55. PubMed ID: 11712792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours.
    Sawyer EJ; Hanby AM; Rowan AJ; Gillett CE; Thomas RE; Poulsom R; Lakhani SR; Ellis IO; Ellis P; Tomlinson IP
    J Pathol; 2002 Apr; 196(4):437-44. PubMed ID: 11920740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
    Vasaturo F; Sallusti E; Gradilone A; Malacrino C; Nardo T; Avagnano G; Aglianò AM; Granato T; De Vincenzi B; Coppotelli G; Marzullo A; Soda G; Simonelli L; Modesti M; Scarpa S
    Int J Oncol; 2005 Oct; 27(4):1005-11. PubMed ID: 16142317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors.
    Landberg G; Ostlund H; Nielsen NH; Roos G; Emdin S; Burger AM; Seth A
    Oncogene; 2001 Jun; 20(27):3497-505. PubMed ID: 11429696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.
    Willipinski-Stapelfeldt B; Riethdorf S; Assmann V; Woelfle U; Rau T; Sauter G; Heukeshoven J; Pantel K
    Clin Cancer Res; 2005 Nov; 11(22):8006-14. PubMed ID: 16299229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors.
    Tse GM; Lui PC; Vong JS; Lau KM; Putti TC; Karim R; Scolyer RA; Lee CS; Yu AM; Ng DC; Tse AK; Tan PH
    Breast Cancer Res Treat; 2009 Apr; 114(3):441-8. PubMed ID: 18443904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
    Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
    In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
    Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
    Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast preserving surgery decision making.
    Schauer A; Marx D; Schauer M; Binder C; Kuhn W; Meden H
    Anticancer Res; 1998; 18(3C):2107-37. PubMed ID: 9703770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptosis-related proteins (Fas, Fas ligand, bcl-2 and p53) in different types of human breast tumors.
    Ben-Hur H; Mordechay E; Halperin R; Gurevich P; Zandbank J; Herper M; Zusman I
    Oncol Rep; 2002; 9(5):977-80. PubMed ID: 12168058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosomal aberrations and genetic relations in benign, borderline and malignant phyllodes tumors of the breast: a comparative genomic hybridization study.
    Lv S; Niu Y; Wei L; Liu Q; Wang X; Chen Y
    Breast Cancer Res Treat; 2008 Dec; 112(3):411-8. PubMed ID: 18189161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.